{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events of special interest (AESIs) were collected.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population.","reportingStatus":"POSTED","timeFrame":"Up to 153 weeks","title":"DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)","type":"SECONDARY","unitOfMeasure":"Participants"}